Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age

Bibliographic Details
Main Author: Torres, Thiago Silva
Publication Date: 2014
Other Authors: Cardoso, Sandra Wagner, Velasque, Luciane de Souza, Santos, Valdiléa Gonçalves Veloso dos, Grinsztejn, Beatriz
Format: Article
Language: eng
Source: Repositório Institucional da FIOCRUZ (ARCA)
Download full: https://www.arca.fiocruz.br/handle/icict/10005
Summary: Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Centro de Pesquisa Clínica de HIV/AIDS. Rio de Janeiro, RJ, Brasil
id CRUZ_68318110fee18fdfac1ec3a5f84c2471
oai_identifier_str oai:www.arca.fiocruz.br:icict/10005
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Torres, Thiago SilvaCardoso, Sandra WagnerVelasque, Luciane de SouzaSantos, Valdiléa Gonçalves Veloso dosGrinsztejn, Beatriz2015-04-15T16:31:18Z2015-04-15T16:31:18Z2014TORRES, Thiago Silva et al. Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age. Brazilian Journal of Infectious Diseases, Salvador, v. 18, n. 1, p. 34-41, 2014.1413-8670https://www.arca.fiocruz.br/handle/icict/1000510.1016/j.bjid.2013.04.0051678-4391engElsevierIncidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by ageinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Centro de Pesquisa Clínica de HIV/AIDS. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Centro de Pesquisa Clínica de HIV/AIDS. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Centro de Pesquisa Clínica de HIV/AIDS. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Departamento de Matemática. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Centro de Pesquisa Clínica de HIV/AIDS. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Centro de Pesquisa Clínica de HIV/AIDS. Rio de Janeiro, RJ, BrasilToxicity is the most frequently reported reason for modifying or discontinuing the first com-bined antiretroviral therapy regimens, and it can cause significant morbidity, poor qualityof life and also can be an important barrier to adherence, ultimately resulting in treatmentfailure and viral resistance. Elderly patients with HIV/AIDS (≥50 years) may have a differ-ent profile in terms of treatment modification due to higher incidence of comorbidities andpolypharmacy. The aim of this study was to describe the incidence of modifying or discon-tinuing first combined antiretroviral therapy regimen due to toxicity (TOX-MOD) during thefirst year of treatment at the IPEC – FIOCRUZ HIV/AIDS cohort, Rio de Janeiro, Brazil, strat-ified by age. Demographic, clinical and treatment characteristics from antiretroviral-naïvepatients who first received combined antiretroviral therapy between Jan/1996 and Dec/2010were collected. Incidence rate and confidence interval of each event were estimated usingquasipoisson model. To estimate hazard ratio (HR) of TOX-MOD during the first year of com-bined antiretroviral therapy Cox’s proportional hazards regression was applied. Overall, 1558patients were included; 957 (61.4%), 420 (27.0%) and 181 (11.6%) were aged <40, 40–49, and≥50 years, respectively. 239 (15.3%) events that led to any modifying or discontinuing withinthe first year of treatment were observed; 228 (95.4%) of these were TOX-MOD, correspondingto an incidence rate of 16.6/100 PY (95% CI: 14.6–18.9). The most frequent TOX-MOD duringfirst combined antiretroviral therapy regimen were hematologic (59; 26.3%), central ner-vous system (47; 20.9%), rash (42; 19.1%) and gastrointestinal (GI) (38; 16.7%). In multivariateanalysis, incidence ratio of TOX-MOD during the first year of combined antiretroviral ther-apy progressively increases with age, albeit not reaching statistical significance. This profilewas maintained after adjusting the model for sex, combined antiretroviral therapy regimenand year of combined antiretroviral therapy initiation. These results are important becausenot only patients are living longer and aging with HIV, but also new diagnoses are being made among the elderly. Prospective studies are needed to evaluate the safety profile of first line combined antiretroviral therapy on elderly individuals, especially in resource-limited countries, where initial regimens are mostly NNRTI-based.AgingAntiretroviralHIVToxicityHIVToxicityAgingAntiretroviral Therapyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82352https://www.arca.fiocruz.br/bitstream/icict/10005/1/license.txtafbdf7d7a9bcf771a1cc7edf5f618413MD51ORIGINALIncidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age.pdfIncidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age.pdfapplication/pdf745565https://www.arca.fiocruz.br/bitstream/icict/10005/2/Incidence%20rate%20of%20modifying%20or%20discontinuing%20first%20combined%20antiretroviral%20therapy%20regimen%20due%20to%20toxicity%20during%20the%20first%20year%20of%20treatment%20stratified%20by%20age.pdf042010d916255bb6c8a40f61a6d7d7beMD52TEXTIncidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age.pdf.txtIncidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age.pdf.txtExtracted texttext/plain39478https://www.arca.fiocruz.br/bitstream/icict/10005/3/Incidence%20rate%20of%20modifying%20or%20discontinuing%20first%20combined%20antiretroviral%20therapy%20regimen%20due%20to%20toxicity%20during%20the%20first%20year%20of%20treatment%20stratified%20by%20age.pdf.txt0f3abf9e305d56487a95e28a296ffbd2MD53icict/100052023-10-05 14:36:16.383oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-10-05T17:36:16Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
title Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
spellingShingle Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
Torres, Thiago Silva
Aging
Antiretroviral
HIV
Toxicity
HIV
Toxicity
Aging
Antiretroviral Therapy
title_short Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
title_full Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
title_fullStr Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
title_full_unstemmed Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
title_sort Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age
author Torres, Thiago Silva
author_facet Torres, Thiago Silva
Cardoso, Sandra Wagner
Velasque, Luciane de Souza
Santos, Valdiléa Gonçalves Veloso dos
Grinsztejn, Beatriz
author_role author
author2 Cardoso, Sandra Wagner
Velasque, Luciane de Souza
Santos, Valdiléa Gonçalves Veloso dos
Grinsztejn, Beatriz
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Torres, Thiago Silva
Cardoso, Sandra Wagner
Velasque, Luciane de Souza
Santos, Valdiléa Gonçalves Veloso dos
Grinsztejn, Beatriz
dc.subject.en.none.fl_str_mv Aging
Antiretroviral
HIV
Toxicity
topic Aging
Antiretroviral
HIV
Toxicity
HIV
Toxicity
Aging
Antiretroviral Therapy
dc.subject.decs.pt_BR.fl_str_mv HIV
Toxicity
Aging
Antiretroviral Therapy
description Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Centro de Pesquisa Clínica de HIV/AIDS. Rio de Janeiro, RJ, Brasil
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2015-04-15T16:31:18Z
dc.date.available.fl_str_mv 2015-04-15T16:31:18Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv TORRES, Thiago Silva et al. Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age. Brazilian Journal of Infectious Diseases, Salvador, v. 18, n. 1, p. 34-41, 2014.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/10005
dc.identifier.issn.none.fl_str_mv 1413-8670
dc.identifier.doi.none.fl_str_mv 10.1016/j.bjid.2013.04.005
dc.identifier.eissn.none.fl_str_mv 1678-4391
identifier_str_mv TORRES, Thiago Silva et al. Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age. Brazilian Journal of Infectious Diseases, Salvador, v. 18, n. 1, p. 34-41, 2014.
1413-8670
10.1016/j.bjid.2013.04.005
1678-4391
url https://www.arca.fiocruz.br/handle/icict/10005
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/10005/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/10005/2/Incidence%20rate%20of%20modifying%20or%20discontinuing%20first%20combined%20antiretroviral%20therapy%20regimen%20due%20to%20toxicity%20during%20the%20first%20year%20of%20treatment%20stratified%20by%20age.pdf
https://www.arca.fiocruz.br/bitstream/icict/10005/3/Incidence%20rate%20of%20modifying%20or%20discontinuing%20first%20combined%20antiretroviral%20therapy%20regimen%20due%20to%20toxicity%20during%20the%20first%20year%20of%20treatment%20stratified%20by%20age.pdf.txt
bitstream.checksum.fl_str_mv afbdf7d7a9bcf771a1cc7edf5f618413
042010d916255bb6c8a40f61a6d7d7be
0f3abf9e305d56487a95e28a296ffbd2
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324886909747200

Similar Items